Extrawell Pharmaceutical Holdings Limited's latest marketcap:
As of 09/26/2025, Extrawell Pharmaceutical Holdings Limited's market capitalization has reached $36.7 M. According to our data, Extrawell Pharmaceutical Holdings Limited is the 32922th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 36.7 M |
| Revenue (ttm) | 7.12 M |
| Net Income (ttm) | 28.61 M |
| Shares Out | 2.55 B |
| EPS (ttm) | 0.01 |
| Forward PE | 0.00 |
| Ex-Dividend Date | 09/16/1999 |
| Earnings Date | 08/29/2025 |
Extrawell Pharmaceutical Holdings Limited's yearly market capitalization.
| Date | Market Cap(HK$) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 09/26/2025 | HK$285.6 M | $36.7 M | 130.46% | 32922 |
| 12/31/2024 | HK$119.5 M | $15.38 M | 47.06% | 35771 |
| 12/29/2023 | HK$81.26 M | $10.4 M | -56.96% | 36944 |
| 12/30/2022 | HK$188.81 M | $24.17 M | -14.13% | 31594 |
| 12/31/2021 | HK$219.88 M | $28.19 M | -28.68% | 30957 |
| 12/31/2020 | HK$308.31 M | $39.75 M | 81.69% | 26018 |
| 12/31/2019 | HK$169.69 M | $21.77 M | -33.02% | 26041 |
| 12/31/2018 | HK$253.34 M | $32.34 M | -50.93% | 23244 |
| 12/29/2017 | HK$516.24 M | $66.06 M | -18.49% | 20130 |
| 12/30/2016 | HK$633.35 M | $81.66 M | -28.38% | 16909 |
Company Profile
About Extrawell Pharmaceutical Holdings Limited
Extrawell Pharmaceutical Holdings Limited is an investment holding company specializing in the development, manufacturing, marketing, and distribution of pharmaceutical products. The company primarily operates in the People’s Republic of China and Hong Kong.
Business Segments
- Manufacturing: Produces pharmaceutical products such as transfer factor oral solution (immune regulator), Wisk (for skin injuries and wound healing), and ZhouBang (thromboxane synthetase inhibitor).
- Trading: Markets and distributes imported pharmaceuticals, including Skin-Cap (for skin conditions) and Millibar (for hypertension).
- Gene Development: Engages in genome-related technology development and commercialization.
Key Products
- Transfer factor oral solution – Treats viral infections and immune deficiencies.
- Wisk – Addresses skin injuries, burns, and ulcers.
- ZhouBang – Prevents platelet coagulation and aids blood vessel relaxation.
- Skin-Cap – Relieves itching, irritation, and skin conditions.
- Millibar – Manages high blood pressure.
Research & Development
The company is developing an oral insulin product, currently in clinical trials, for diabetes treatment.
Additional Activities
- Provides agency services.
- Engages in property investment.
Founded: 1998
Headquarters: Quarry Bay, Hong Kong
Frequently Asked Questions
-
What is Extrawell Pharmaceutical Holdings Limited's (HKG-0858) current market cap?As of 09/26/2025, Extrawell Pharmaceutical Holdings Limited (including the parent company, if applicable) has an estimated market capitalization of $36.7 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Extrawell Pharmaceutical Holdings Limited (HKG-0858) rank globally by market cap?Extrawell Pharmaceutical Holdings Limited global market capitalization ranking is approximately 32922 as of 09/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.